Day: December 3, 2018

Mr. Y. Mark Xu, Chairman of Xynomic Pharma Presented at the BioCentury China Healthcare Summit 2018

From Startup Xynomic Pharma Link to Full Article: China’s Globally Facing Future: How China’s healthcare pathfinders are leveraging the nation’s innovation, policy initiatives and access to capital markets in HK and domestic exchanges to build a globally facing industry. Five years ago, the first China Healthcare Summit asked how the nation would

Aptinyx Reports Positive Data from Interim Analysis of Exploratory Study of NYX-2925 in Subjects with Fibromyalgia

From Startup Aptinyx Link to Full Article: Achieved statistical significance on primary imaging-based endpoint, changes in markers of central pain processing, in 11 subjects Observed corresponding trends of improvement on multiple secondary endpoints, including average daily pain scores and the Revised Fibromyalgia Impact Questionnaire (FIQR) Data support further development

Magenta Therapeutics Presents Preclinical Data on Targeted Non-Genotoxic Conditioning Programs Demonstrating Potent Stem Cell Depletion and Anti-Leukemia Survival Benefit

From Startup Magenta Therapeutics Link to Full Article: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 2, 2018– Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that the Company presented preclinical research on its targeted conditioning programs at

Magenta Therapeutics Presents New Data from Phase 2 Study of MGTA-456 Cell Therapy in Patients with Inherited Metabolic Disorders

From Startup Magenta Therapeutics Link to Full Article: – All five patients with inherited metabolic disorders (IMDs) treated with MGTA-456 in ongoing Phase 2 study met the primary endpoint of successful engraftment – – Patients with cerebral adrenoleukodystrophy (cALD) showed resolution of brain inflammation on MRI as early as

Aduro Biotech and Dana-Farber Cancer Institute Present Preclinical Data Supporting Anti-APRIL Antibody BION-1301 for the Treatment of Multiple Myeloma at the 60th American Society of Hematology Annual Meeting and Exposition

From Startup Aduro Biotech Link to Full Article: BERKELEY, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) — Aduro Biotech, Inc. (NASDAQ: ADRO) today announced preclinical data in two abstracts for its first-in-class anti-APRIL antibody BION-1301 supporting its potential use as a treatment for multiple myeloma (MM) at the 60thAmerican Society of